MedTrace Logo

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

NCT02735629 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-07-28

No results posted yet for this study

Summary

The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil. The study will also investigate whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with remifentanil.

Conditions

  • Opiate Induced Respiratory Depression

Interventions

DRUG

CX1739 - 300 mg

Ampakine CX1739 - 300 mg

DRUG

CX1739 - 600 mg

CX1739 - 600 mg

DRUG

CX1739 - 900 mg

CX1739 - 900 mg

DRUG

Placebo

Placebo to 300 mg CX1739

Sponsors & Collaborators

Principal Investigators

  • Richard Purcell · RespireRx Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-08-31
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02735629 on ClinicalTrials.gov